The epigenomics revolution in myelodysplasia: A clinico-pathological perspective

Pathology

Volumn 43, Issue 6, 2011, Pages 536-546

  Tan, Peter T ^a   Wei, Andrew H ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Azacitidine; Epigenetic; Hypomethylating; Methylation; Myelodysplastic syndrome

Indexed keywords

EID: 81555216957     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834a4061     Document Type: Article

References (136)

1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodys-plastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32.
3. Bird AP. Cp G-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13. (Pubitemid 16016411)
4. Wolffe AP, Jones PL, Wade PA. DNA demethylation. Proc Natl Acad Sci USA 1999; 96: 5894-6. (Pubitemid 29256591)
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54. (Pubitemid 37448928)
6. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplas-tic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2 (Suppl 1): S24-9.
7. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE. Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother Rep 1972; 56: 413-9.
8. Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ. 5-azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973; 42: 359-65.
9. Ginder GD, Whitters M, Kelley K, Chase RA. In vivo demethylation of chicken embryonic beta-type globin genes with 5-azacytidine. Prog Clin Biol Res 1983; 134: 501-10.
10. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93. (Pubitemid 10117303)
11. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983; 84: 202-11.
12. Friedman S. The inhibition of DNA(cytosine-5)methylases by 5-azacy-tidine. The effect of azacytosine-containing DNA. Mol Pharmacol 1981; 19: 314-20. (Pubitemid 11004237)
13. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40. (Pubitemid 34525728)
14. Silverman LR, Mc Kenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and9221 bythe Cancer and Leukemia Group B.J Clin Oncol 2006; 24: 3895-903. (Pubitemid 46630737)
15. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-8. (Pubitemid 40685574)
16. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-8.
17. Raza A, Raza FZ, Galili N. Low-dose decitabine and high-risk MDS. Blood 2006; 108: 4291; author reply 91-2.
18. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelody-splastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-7. (Pubitemid 46053042)
19. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006; 106: 1794-803.
20. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk mye-lodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized Phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-96.
21. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-28.
22. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLo S One 2010; 5: e9001.
23. Kouzarides T Chromatin modifications and their function. Cell 2007; 128: 693-705. (Pubitemid 46273577)
24. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-74.
25. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-4. (Pubitemid 28099682)
26. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-Cp G-binding protein Me CP2 involves a histone deacetylase com-plex. Nature 1998; 393: 386-9. (Pubitemid 28269714)
27. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88. (Pubitemid 27132124)
28. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99. (Pubitemid 12073508)
29. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001; 351.
30. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008; 439.
31. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-25. (Pubitemid 44061337)
32. List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without com-plete remission. ASCO Meeting Abstracts 2008; 26: 7006.
33. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelo-dysplastic syndromes. J Clin Oncol 2007; 25: 3503-10. (Pubitemid 47315575)
34. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.
35. Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol 2008; 26: 1180; author reply 81-2.
36. Greenberg P, Tuechler H, Schanz J, et al. 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leukemia Res 2011; 35: S6-16.
37. Schanz J, Tüchler H, Sole F, et al. Proposal of a new, comprehensive cytogenetic scoring system for primary MDS. Haematologica 2010; 95: 219.
38. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005; 74: 481-514. (Pubitemid 40995515)
39. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.
40. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by Methy Light. Nucleic Acids Res 2005; 33: 6823-36. (Pubitemid 41830488)
41. Ehrlich M, Gama-Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982; 10: 2709-21.
42. Karimi M, Johansson S, Stach D, et al. LUMA (LUminometric Methyla-tion Assay)\-a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res 2006; 312: 1989-95. (Pubitemid 43850924)
43. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-22.
44. Frommer M, Mc Donald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827-31.
45. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454: 766-70.
46. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37: 853-62. (Pubitemid 41077111)
47. Jacinto FV, Ballestar E, Esteller M. Methyl-DNA immunoprecipitation (Me DIP): hunting down the DNA methylome. Biotechniques 2008; 44: 35; 37, 39.
48. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010; 38: 391-9.
49. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 2009; 1: 177-200.
50. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG. Whole-genome DNA methylation profiling using Methyl Cap-seq. Methods 2010; 52: 232-6.
51. Khulan B, Thompson RF, Ye K, et al. Comparativeisoschizomerprofiling of cytosine methylation: the HELP assay. Genome Res 2006; 16: 1046-55. (Pubitemid 44162264)
52. Costello JF, Plass C, Cavenee WK. Restriction landmark genome scan-ning. Methods Mol Biol 2002; 200: 53-70.
53. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-905. (Pubitemid 41077119)
54. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of Cp G islands. Proc Natl Acad Sci USA 1996; 93: 9821-6. (Pubitemid 26296693)
55. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 2008; 36: e42.
56. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methyla-tion assay. Nucleic Acids Res 1997; 25: 2532-4. (Pubitemid 27303718)
57. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of Cp G sites. Biotechniques 2003; 35: 146-50. (Pubitemid 36828724)
58. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005; 102: 15785-90. (Pubitemid 41552820)
59. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007; 35: e41.
60. Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 2008; 1: 7.
61. Murrell A, Rakyan VK, Beck S. From genome to epigenome. Hum Mol Genet 2005; 14 (Spec No 1): R3-10.
62. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997; 90: 1403-9. (Pubitemid 27355412)
63. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-90. (Pubitemid 28227550)
64. Tien HF, Tang JL, Tsay W, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transforma-tion. Br J Haem 2001; 112: 148-54. (Pubitemid 32151162)
65. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007; 21: 1937-44. (Pubitemid 47299967)
66. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76: 23-32.
67. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-13.
68. Esteller M. Cancer epigenomics: DNA methylomes and histone-modifi-cation maps. Nat Rev Genet 2007; 8: 286-98. (Pubitemid 46439286)
69. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-25.
70. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448-58.
71. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120. (Pubitemid 32662206)
72. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75-83. (Pubitemid 32980246)
73. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003; 983: 84-100. (Pubitemid 36399322)
74. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y Role of Tet proteins in 5m C to 5hm C conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-33.
75. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-5.
76. Mohamedali AM, Smith AE, Gaken J, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27: 4002-6.
77. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-42.
78. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-32.
79. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-301.
80. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-43.
81. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-91.
82. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
83. Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-506.
84. Kulasekararaj AG, Mohamedali AM, Smith AE, et al. Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. Blood (ASHAnnual Meeting Abstracts) 2010; 116: 125.
85. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636.
86. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24: 1094-6.
87. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 func-tion, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-67.
88. Caramazza D, Lasho TL, Finke CM, et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 2010; 24: 2120-2.
89. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668-74.
90. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-33.
91. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309-15.
92. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; Mar 18: Epub ahead of print.
93. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-95. (Pubitemid 351377805)
94. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-7.
95. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-6.
96. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-9.
97. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733-43.
98. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syn-dromes treated with azacitidine. Blood 2011; 117: 403-11.
99. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hyper-methylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-64.
100. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361-9.
101. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-73.
102. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-40. (Pubitemid 38268953)
103. Yang AS, Doshi KD, Choi S-W, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495-503. (Pubitemid 43844978)
104. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acutemyeloidleukemiaandmyelodysplastic syndrome. Blood 2007; 110: 2302-8. (Pubitemid 47523148)
105. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-9.
106. Ortmann CA, Eisele L, Nuckel H, et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 2008; 87: 809-18.
107. Guo ZS, Hong JA, Irvine KR, et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66: 1105-13. (Pubitemid 43165979)
108. Dubovsky JA, Mc Neel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethy-lating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009; 15: 3406-15.
109. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-18.
110. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expertpanel opinion. Leuk Res 2010; 34: 1410-6.
111. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-6. (Pubitemid 351213383)
112. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; Apr 15: Epub ahead of print..
113. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29: 2521-7.
114. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90. (Pubitemid 46087907)
115. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
116. Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827-34.
117. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226-35.
118. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-9. (Pubitemid 39166498)
119. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; 112: 981-9.
120. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781-90. (Pubitemid 46482071)
121. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) de-monstrating efficacy in patients with advanced hematologic malignancies. Blood (ASHAnnual Meeting Abstracts) 2008; 112: 958.
122. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67. (Pubitemid 40170861)
123. Gore SD. Six (or more) drugs in search of a mechanism: DNA methyl-transferase and histone deacetylase inhibitors in the treatment of myelo-dysplastic syndromes. J Natl Compr Canc Netw 2006; 4: 83-90. (Pubitemid 44265383)
124. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-7. (Pubitemid 29036293)
125. Fenaux P, De Angelo DJ, Garcia-Manero G, et al. Phase Ib study of oral panobinostat in combination with 5-azacitidine (5-aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Blood (ASH Annual Meet-ing Abstracts) 2010; 116: 4957.
126. Uy GL, Abboud CN, Cashen AF, et al. Phase I study of panobinostat plus decitabine in elderly patients with advanced MDS or AML. Blood (ASH Annual Meeting Abstracts)2010; 116: 1060.
127. Issa J-P, Castoro R, Ravandi-Kashani F, et al. Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. Blood (ASH Annual Meeting Abstracts) 2008; 112: 228.
128. Garcia-Manero G, Estey EH, Jabbour E, et al. Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance or presence of othercomorbidities. Blood (ASH Annual Meeting Abstracts) 2010; 116: 604.
129. Kirschbaum M, Gojo I, Goldberg SL, et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 2008; 112: 3651.
130. Prebet T, Gore SD, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodys-plasia-related changes: results of the US Leukemia Intergroup Trial E1905. Blood (ASH Annual Meeting Abstracts) 2010; 116: 601.
131. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) in-hibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2007; 110: 444.
132. Krug UO, Koschmieder A, Gerss J, et al. Addition of 5-azacitidine to standard induction therapy is feasible in older patients with acute myeloid leukemia: the AML-AZA trial of the SAL Study Group. Blood (ASH Annual Meeting Abstracts) 2010; 116: 2180.
133. Rucker FG, Stilgenbauer S, Bommer M, et al. Induction therapy with idarubicin and etoposide combined with sequential or concurrent azaci-tidine in patients with high-risk acute myeloid leukemia: pilot-phase of the AMLSG 12-09 study. Blood (ASH Annual Meeting Abstracts) 2010; 116: 2184.
134. Parikh SA, Kantarjian H, Garcia-Manero G, et al. Clofarabine plus low-dose cytarabine induction followed by consolidation with clofarabine plus low-dose cytarabine alternating with decitabine as frontline therapy for patients with acute myeloid leukemia (AML) < = 60 years. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2058.
135. Krauter J, Schlenk RF, Schaich M, et al. A phase Ib dose-finding study of oral panobinostat in combination with cytarabine (ara-C) and mitoxan-trone as salvage therapy for refractory or relapsed acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2010; 116: 3310.
136. Garcia-Manero G, Tambaro FP, Bekele N, et al. Final report of a phase II trial of vorinostat, idarubicin and cytarabine in previously untreated acute myelogenous leukemia (AML) or high risk myelodysplastic syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 2010; 116: 2189.